CMC Biologics, a global leader in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic proteins, and AGC Asahi Glass, a world-leading manufacturer of glass, chemicals and high-tech materials, announced on 20 December 2016 that they have entered into a definitive agreement with CMC Biologics' shareholders including Monitor Clipper Partners, European Equity Partners and Innoven Partenaires, by which AGC Asahi Glass will acquire 100% of CMC Biologics' shares.
The acquisition was closed on 1 February 2017.
Founded in Denmark in 2001 as a start-up company, CMC Biologics has grown to be one of the most valued independent CDMO companies in the world. Today with over 500 employees, two commercial-phase manufacturing facilities, and one early-phase manufacturing facility, CMC Biologics is one of the leaders in the biologics CDMO industry. CMC Biologics will retain its distinct brand and independence after the transaction.
Søren Brinkmann of Brinkmann Kronborg Henriksen has represented CMC Biologics since 2005, and together with Stefan Westh Wiencken (associate) he represented the company in this transaction with Danish law issues. The global lead advisors were Shearman Sterling (legal) and William Blair (financial). If you have questions regarding the transaction or Brinkmann Kronborg Henriksen's M&A capabilities, you can contact Søren (firstname.lastname@example.org).
Brinkmann Kronborg Henriksen has extensive experience advising international and Danish businesses on mergers and acquisitions in Denmark. We work closely with investment banks and corporate finance advisory teams to ensure an optimal transactional structure for our clients. Our experiences include venture capital, private equity, joint ventures/strategic alliances, generational successions and equity crowdfunding. We assist with, among other things, cross-border project management, negotiation of sale/purchase and investment agreements as well as shareholders’ agreements.
Other press releases: